ADiTx Therapeutics
General Information | |
Business: |
We are a preclinical stage life sciences company with a mission to prolong life and enhance life quality of patients who have undergone organ transplants. The discovery of immunosuppressive (anti-rejection) drugs over 40 years ago has made possible life-saving organ transplantation procedures. While these drugs prevent or delay organ rejection, transplanted organs often ultimately fail, and about 40% of transplanted organs survive no more than 5 years. Furthermore, immune suppression leads to significant undesirable side effects, such as increased susceptibility to life-threatening infections and cancers, because it is not specifically targeted towards the transplanted organs; rather, it indiscriminately and broadly suppresses immune function throughout the body.
|
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 18 |
Founded: | 2017 |
Contact Information | |
Address | 11161 Anderson Street, Suite 105-10014, Loma Linda, CA 92354, US |
Phone Number | (909) 488-0844 |
Web Address | http://www.aditxt.com |
View Prospectus: | ADiTx Therapeutics |
Financial Information | |
Market Cap | $47.5mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-5.8 mil (last 12 months) |
IPO Profile | |
Symbol | ADTX |
Exchange | NASDAQ |
Shares (millions): | 1.2 |
Price range | $9.00 - $9.00 |
Est. $ Volume | $11.0 mil |
Manager / Joint Managers | Dawson James Securities |
CO-Managers | - |
Expected To Trade: | 6/30/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |